Summary
- Relay Therapeutics has filed to raise $200 million in an IPO, although the final figure may differ.
- The firm is advancing a pipeline of treatment candidates for solid tumors.
- RLAY is just entering Phase 1 trials for its lead candidate, so the firm is still very early stage.
- Looking for more stock ideas like this one? Get them exclusively at IPO Edge. Get started today »
Quick Take
Relay Therapeutics (RLAY) has filed to raise $200 million in an IPO of its common stock, according to an S-1 registration statement.
The company is advancing a pipeline of small molecule medicines that promise to treat solid tumors in a highly targeted fashion.
RLAY is just entering Phase 1 trials for its lead candidate, so is still a very early stage firm.
I’ll provide an update when we learn more IPO details from management.
Company & Technology
Cambridge, Massachusetts-based Relay was founded to focus its drug efforts on precision oncology treatments for solid tumors, however its Dynamo platform may have applications in other areas of precision medicine, including genetic disease.
Management is headed by president and Chief Executive Officer Sanjiv Patel, M.D., who has been with the firm since March 2017 and was previously Executive Vice President, Chief Strategy Officer at Allergan, where he held other senior roles.
Below is a brief overview video of precision oncology:
